Medplus Health Services Limited (NSE: MEDPLUS, BSE: 543427) is a Hyderabad, Telangana-based company in the Drug Stores and Pharmacies industry. With a market capitalisation of ₹7,386 Cr, it ranks #693 by market cap among the 6,197 Indian listed companies on FinBizNet. At ₹617.00 (as of 16 Nov 2026), the share price is 39.6% below its 52-week high of ₹1,022.20 and 9.1% above its 52-week low of ₹565.60. The share price is down 21.1% over one year and down 7.3% over three months.
| Current Price | ₹617.00 |
|---|---|
| Market Cap | ₹7,386 Cr |
| NSE Symbol | MEDPLUS |
| BSE Code | 543427 |
| Sector | Consumer Staples > Consumer Staples Distribution and Retail > Consumer Staples Distribution and Retail |
| Sub-Industry | Drug Retail > Drug Stores and Pharmacies |
| P/E Ratio | 34.2 |
| Return on Equity | 11.82% |
| Return on Assets | 5.86% |
| 52-Week Range | ₹565.60 – ₹1,022.20 |
| 1-Year Price Change | -21.1% |
| 3-Month Price Change | -7.3% |
| Beta (1Y) | 0.03 |
| Headquarters | Hyderabad, Telangana |
| Website | www.medplusindia.com |
| Revenue | ₹2,037 Cr |
|---|---|
| Net Profit | ₹56 Cr |
| Net Margin | 2.8% |
| EPS (Basic) | ₹4.73 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Medplus Health Services Limited reported revenue of ₹2,037 Cr in Q2 FY27, up 21.3% from ₹1,679 Cr in Q2 FY26 and up 8.4% from ₹1,880 Cr in Q1 FY27. It posted a net profit of ₹56 Cr for the quarter, against a net profit of ₹56 Cr in Q2 FY26 (up 1.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1,510 Cr (Q4 FY25) to ₹2,037 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹2,037 Cr | ₹56 Cr | 2.8% |
| Q1 FY27 | ₹1,880 Cr | ₹33 Cr | 1.8% |
| Q4 FY26 | ₹1,864 Cr | ₹64 Cr | 3.4% |
| Q3 FY26 | ₹1,806 Cr | ₹58 Cr | 3.2% |
| Q2 FY26 | ₹1,679 Cr | ₹56 Cr | 3.3% |
| Q1 FY26 | ₹1,543 Cr | ₹42 Cr | 2.7% |
| Q4 FY25 | ₹1,510 Cr | ₹51 Cr | 3.4% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 40.19% of Medplus Health Services Limited's shares as of Sept 2026, against 40.29% in Sept 2025 (−0.10 percentage points). Delivery averaged 52.7% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, such as prescription medicines, over-the-counter drugs, vitamins, medical devices, and diagnostic test kits; and fast-moving consumer goods (FMCG), including personal and home care products like toiletries, baby care items, soaps, detergents, and sanitizers. The company also engages in wholesale cash and carry; provision of diagnostic, pathological, and laboratory testing services, as well as contract manufacturing of private-label pharmaceuticals, wellness products, and FMCG goods; and operates diagnostic centres. It distributes its products through retail and online channels. The company was incorporated in 2006 and is based in Hyderabad, India.
1. Wholesale-This segment engages in the wholesale cash and carry business. 2. Retail-This segment engages in the retail trading of medicines and general items. 3. Diagnostic Testing Services-This segment provides pathological testing services. 4. Unallocated-0
1. Retail-98.1% 2. Diagnostic Services-1.9% 3. Others-0%
Medplus Health Services Limited is trading at ₹617.00, with a market capitalisation of ₹7,386 Cr.
Medplus Health Services Limited operates in the Consumer Staples > Consumer Staples Distribution and Retail > Consumer Staples Distribution and Retail space (Drug Retail > Drug Stores and Pharmacies).
Medplus Health Services Limited has a P/E of 34.2 and a return on equity of 11.82%.
Medplus Health Services Limited is listed on the NSE under the symbol MEDPLUS and on the BSE under the scrip code 543427.
Medplus Health Services Limited's share price is down 21.1% over one year and down 7.3% over three months. Its 52-week range is ₹565.60 to ₹1,022.20.
In Q2 FY27, Medplus Health Services Limited reported revenue of ₹2,037 Cr and net profit of ₹56 Cr, with basic EPS of ₹4.73 (consolidated, parsed from the company's exchange filing).
Medplus Health Services Limited reported revenue of ₹2,037 Cr in Q2 FY27, up 21.3% from ₹1,679 Cr in Q2 FY26 and up 8.4% from ₹1,880 Cr in Q1 FY27.
Promoters held 40.19% of Medplus Health Services Limited's shares as of Sept 2026, against 40.29% in Sept 2025 (−0.10 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.